Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Haematological Malignancies

Next Previous
Trial Profile

A Modular Phase I/II, Open-label, Multicentre Study to Assess AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Haematological Malignancies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acalabrutinib (Primary) ; AZD-4573 (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 09 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 21 Feb 2025 Time frame of primary endpoint changed from Screening (Day -30 to Day -1) until disease progression or survival until death (approximately 6 months) to Screening (Day -30 to Day -1) until disease progression or survival until death (approximately 2.5 years).
  • 21 Feb 2025 Planned End Date changed from 31 Dec 2024 to 28 Feb 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top